Zometa, Aredia "Dear Doctor" Letter Sent To Dentists On Jaw Osteonecrosis Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis notifies 150,000 dental health professionals about the risk of osteonecrosis of the jaw in patients receiving intravenous bisphosphonates. FDA's Oncologic Drugs Advisory Committee had urged Novartis to notify dentists after an earlier "Dear Doctor" letter was sent to oncologists, hematologists, oral surgeons and urologists.